BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33394756)

  • 1. CORR Insights®: Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
    Tang X
    Clin Orthop Relat Res; 2021 Apr; 479(4):853-854. PubMed ID: 33394756
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
    Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
    Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
    Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
    Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical utility of real-time fluorescent PCR for combined detection of anaplastic lymphoma kinase and c-ros oncogene 1 receptor tyrosine kinase in non-small cell lung cancer].
    Bai DY; Zhang HP; Zhong S; Suo WH; Gao DH; Ding Y; Tu JH
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):898-903. PubMed ID: 27998465
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.
    Mitiushkina NV; Romanko AA; Preobrazhenskaya EV; Tiurin VI; Ermachenkova TI; Martianov AS; Mulkidjan RS; Sokolova TN; Kholmatov MM; Bizin IV; Ivantsov AO; Yatsuk OS; Zaitseva OA; Iyevleva AG; Kuligina ES; Imyanitov EN
    Cancer Med; 2022 Sep; 11(17):3226-3237. PubMed ID: 35322575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
    Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
    BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ROS1 fusions in cancer: a review.
    Uguen A; De Braekeleer M
    Future Oncol; 2016 Aug; 12(16):1911-28. PubMed ID: 27256160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET, ROS1 and ALK fusions in lung cancer.
    Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y
    Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.
    Ou SH; Chalmers ZR; Azada MC; Ross JS; Stephens PJ; Ali SM; Miller VA
    Lung Cancer; 2015 Jun; 88(3):352-4. PubMed ID: 25851827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
    [No Abstract]   [Full Text] [Related]  

  • 18. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
    Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
    J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.
    Cai L; Duan J; Qian L; Wang Z; Wang S; Li S; Wang C; Zhao J; Zhang X; Bai H; Wang J
    Front Immunol; 2020; 11():527750. PubMed ID: 33324391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
    Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
    Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.